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Implementation of New Vascular Treatments - an ESVS Executive Committee
Position StatementInnovation is the driving force for improving results after
vascular procedures: prior achievements led to the endo-
vascular revolution, dramatically changing today’s vascular
practice and enabling specialists to treat patients more
safely, with lower morbidity and short term mortality.
We are naturally interested in treating patients in the
best possible way, not just as efﬁciently as possible, but also
by critically and continuously improving patient care.
Courage and humility are essential: both attitudes must be
balanced when evaluating promising new techniques or
products with potentially exciting beneﬁts. Successful pio-
neers are rewarded by publications in high impact factor
journals, appreciation from sponsoring companies, and
gratitude from their patients. New techniques may some-
times be adopted quickly into clinical practice, driven by
ingenious designs and successful preliminary reports. This
can lead to widespread distribution and early agreements
to reimbursement. Legislation differs around the world.
Introduction of new medical devices to the market has until
recently generally been easier in Europe than in the United
States or Japan, resulting in earlier introduction of several
new techniques and products on the European market,
often after only relatively small and short observational
studies. This seems astonishing if you look back at the last
30 years of vascular device invention: almost every make of
ﬁrst generation endovascular aortic repair (EVAR) grafts
were explanted due to long term failures.1
Shorter hospital stay and lower peri-procedural morbidity
are important early beneﬁts of innovative techniques or
new products. As patients appear to beneﬁt, these advan-
tages are highlighted by surgeons and manufacturers.
Sometimes patients ask for these new techniques and urge
us to use the newest and most promising treatment avail-
able long before beneﬁts are proven or long term results
are available.
Compared with plain balloon angioplasty and bare metal
stents, drug coated percutaneous transluminal angioplasty
(PTA) balloons and stents may indeed offer beneﬁts to
patients, with better freedom from target lesion revascu-
larisation and longer patency, supposedly without serious
consequences.2 However, recent, worrying results from a
meta-analysis on long term mortality from these devices1078-5884/ 2019 Published by Elsevier B.V. on behalf of European Society
for Vascular Surgery.
https://doi.org/10.1016/j.ejvs.2019.08.009have disturbed the vascular community, raising concerns
about accreditation of new devices.3 Conﬂicting messages
from regulatory bodies (US Food and Drug Administration)
have been released, because available data were insufﬁ-
cient to give clear answers.4
How sound are these data before new practices are
introduced? Current important non-commercial clinical tri-
als have been temporarily paused showing that there is a
clear need for reliable research, especially into long term
outcomes.5,6 Additionally, just before the current paclitaxel
issue in peripheral vascular angioplasty, the Nellix (endo-
vascular aneurysm sealing, EVAS) device for aortic aneu-
rysm sealing was recalled following reports about serious
failures, despite promising early post-market results.7 By
the time they were withdrawn, both EVAS and drug coated
peripheral devices had been widely used by physicians,
based on limited long term outcome data.
As physicians and clinical researchers, it is our re-
sponsibility to assess reliable long term outcomes before
exposing our patients to new devices and techniques. Out-
comes should be based on unbiased, well powered rando-
mised clinical trials, long term safety studies and real world
practice. Device and pharmaceutical companies play a major
role here, there is real mutual interest in new evidence. But
bias still exist for industry and researchers: intervention trials
are often industry sponsored and trial design data moni-
toring and stopping rules may still be subject to interference,
as well as disputes on ownership of data.
Innovation needs long term proof of safety for devices
and drugs. It may not be ethical to stop a trial early, only
because early beneﬁt appears “proven” (it might be, with
longer follow up and more patients, that the trial shows no
beneﬁt, or even harm?).8 How do we protect our patients
from potentially harmful innovations, while still encour-
aging research? Certainly, beneﬁts from innovations should
be made available as early as possible, with prompt inves-
tigation and close follow up in properly conducted, unbi-
ased prospective trials and long term follow up in registries
and trials. We also need international clinical trial centres,
with clinical trial leaders, approved safety monitoring and
good clinical practice (GCP) certiﬁcation to achieve sound
and well proven data.
Funding should be independent. International healthcare
policies should be harmonised to achieve best possible
medical care: this may play a central role in the future of
clinical research. This will require each country to sign up to
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and reproducible study. Clinical trial purpose, design, size,
and outcome values need independent evaluation. Clinical
trial centres may be unbiased, but they will also need a
thorough knowledge of the ﬁeld of research and of the
clinical environment and purpose for conducting any pro-
posed trial, as well as an appreciation of the healthcare
economics for the whole partnership. The European Union
has now introduced new medical device rules (EU-MDR),
which come into force on 27 May 2020, following a three
year transition period. These rules aim to increase patient
safety, ex ante control for high risk devices, criteria for
notiﬁed bodies, risk classiﬁcation system for in vitro diag-
nostic medical devices, improved transparency, “implant
card” (unique device identiﬁcation [UDI]). Additionally, rules
on clinical evidence and coordination mechanisms have
been introduced. The need for lifelong product evaluation
of all medical devices is fully in line with the points dis-
cussed in this Editorial. However, the new EU-MDR might
place European vascular surgeons in the back seat in terms
of innovation and progress of vascular surgery, should
companies choose to prioritise other markets with a lower
regulatory threshold for introduction of new techniques.
Therefore, there is a global need for balanced and appro-
priate measures to enable the safe introduction of new
treatments to the European market in line with new regu-
lations, to achieve the best patient care worldwide. The
European Society for Vascular Surgery (ESVS) and vascular
surgeons in Europe will have a clear leading role here.
Post-market surveillance is mandatory to assure long
term safety. Device registries have been introduced to
achieve this. Strict regulatory rules may lead to a reduced
number of innovations reaching the market; however,
improved safety should also be achieved. Manufacturers
are now responsible for generating future post-market data.
Any discussion on randomised clinical trials generating
insufﬁcient evidence vs. improving registry based research
with its focus on “real world evidence” will probably
continue. Real world evidence from registries is an impor-
tant adjunct to meaningful randomised clinical trial
research, where external and internal validation plays a
major role. Although we may not be able to prevent long
term failures in medical devices or innovative techniques,
we can do our best to ensure that failures are detected as
early as possible e before widespread clinical use.
What is the role of vascular surgeons in all this? First, we
have to realise that there would be no product failures had
we not used the failing devices. We should be critical when
exposed to new products. Is there a need for it and is there
good evidence behind the introduction (clinical data)?
However, we are aware that for numerous reasons there
will never be randomised controlled trials and long term
clinical data for all new products when introduced to the
market. A way forward for the vascular surgeon under these
circumstances would be to use new products only where
the manufacturer provides a sound international registrywhere all use is entered, followed, and continuously eval-
uated by third party authority.
Before concluding, let us have a close look at the recent
report of long term data from the Veteran Affairs Open
Versus Endovascular Repair (OVER) trial. At median follow
up of 9.4 years (interquartile range 5.7e11.2 years), there
was no difference in the primary outcome of all cause
mortality between patients with an asymptomatic abdom-
inal aortic aneurysm treated by EVAR or open repair (OR),
but more patients in the EVAR group underwent secondary
procedures.9 Interestingly, during the ﬁrst four years of
follow up, overall survival appeared to be higher with EVAR
than OR; from year four to year eight, overall survival was
higher in the OR group; and after eight years, overall sur-
vival was once again higher in the EVAR group. Although
none of these trends were signiﬁcant, this emphasises the
importance of extended follow up of these patients in
whom procedures were performed more than a decade
ago.
The leadership of the ESVS and the editors of the Euro-
pean Journal of Vascular and Endovascular Surgery (EJVES)
strongly encourage the conduct of high quality studies
reporting long term follow up. Only with this objective in
mind will we continue to deliver the best possible care to
our patients.10
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